877664-12-5 Usage
Molecular weight
291.35 g/mol
The sum of the atomic weights of all the atoms in the molecule is approximately 291.35 grams per mole.
Structure
1-Pyrrolidinecarboxylic acid, 2-[(dimethylamino)methyl]-5-[[[trans-4-(methoxycarbonyl)cyclohexyl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S,5S)-
The molecule has a pyrrolidine ring with a carboxylic acid group attached to the 1-position, a dimethylaminomethyl group at the 2-position, and a trans-cyclohexyloxymethyl group at the 5-position. The ester functional group is also present, and the molecule has (2S,5S) stereochemistry.
Derivative of GABA
γ-aminobutyric acid (GABA)
Pregabalin is derived from the neurotransmitter GABA, which is an inhibitory neurotransmitter in the central nervous system.
Mechanism of action
Decreases the release of certain neurotransmitters in the brain
Pregabalin works by reducing the release of specific neurotransmitters, which in turn decreases the transmission of pain signals in the brain.
Medicinal uses
Epilepsy, neuropathic pain, fibromyalgia, generalized anxiety disorder
Pregabalin is used to treat various conditions, including epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder.
Administration
Oral
Pregabalin is typically taken orally in the form of capsules or tablets.
Efficacy
Reduces the frequency and severity of seizures, alleviates nerve pain and anxiety symptoms
Pregabalin has been shown to be effective in reducing both the frequency and severity of seizures, as well as providing relief from nerve pain and anxiety symptoms.
Common side effects
Dizziness, drowsiness, weight gain, dry mouth
Some of the more common side effects experienced by patients taking pregabalin include dizziness, drowsiness, weight gain, and dry mouth.
Serious adverse effects
Allergic reactions, suicidal thoughts
In some cases, pregabalin may cause more serious adverse effects, such as allergic reactions and suicidal thoughts. Patients should consult their healthcare provider if they experience any of these symptoms.
Check Digit Verification of cas no
The CAS Registry Mumber 877664-12-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,6,6 and 4 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 877664-12:
(8*8)+(7*7)+(6*7)+(5*6)+(4*6)+(3*4)+(2*1)+(1*2)=225
225 % 10 = 5
So 877664-12-5 is a valid CAS Registry Number.
877664-12-5Relevant academic research and scientific papers
A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: Trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6- benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy] cyclohexanecarboxylic acid
Setoguchi, Masaki,Iimura, Shin,Sugimoto, Yuuichi,Yoneda, Yoshiyuki,Chiba, Jun,Watanabe, Toshiyuki,Muro, Fumihito,Iigo, Yutaka,Takayama, Gensuke,Yokoyama, Mika,Taira, Tomoe,Aonuma, Misato,Takashi, Tohru,Nakayama, Atsushi,MacHinaga, Nobuo
, p. 42 - 61 (2013/02/22)
We have carried out the optimization of substituents at the C-3 or the C-5 position on the pyrrolidine ring of VLA-4 antagonist 3 with 2-(phenylamino)-7- fluorobenzoxazolyl moiety for the purpose of improving in vivo efficacy while maintaining good aqueous solubility. As a result, we successfully increased in vitro activity in the presence of 3% human serum albumin and achieved an exquisite lipophilic and hydrophilic balance of compounds suitable for oral administrative regimen. The modification resulted in the identification of zwitterionic compound 7n with (5S)-[methoxy(methyl)amino]methylpyrrolidine, which significantly alleviated bronchial hyper-responsiveness to acetylcholine chloride at 12.5 mg/kg, p.o. in a murine asthma model and showed favorable aqueous solubility (JP1, 89 μg/mL; JP2, 462 μg/mL). Furthermore, this compound showed good oral bioavailability (F = 54%) in monkeys.
